サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：髄膜炎菌ワクチンの世界市場（タイプ別：多糖類、結合型ワクチン、混合ワクチン、髄膜炎菌B型ワクチン、その他）：業界分析、市場規模、シェア、成長、動向、予測（2022年～2031年）
市場調査レポート
商品コード
1101519

髄膜炎菌ワクチンの世界市場（タイプ別：多糖類、結合型ワクチン、混合ワクチン、髄膜炎菌B型ワクチン、その他）：業界分析、市場規模、シェア、成長、動向、予測（2022年～2031年）

Meningococcal Vaccines Market (Type: Polysaccharide, Conjugate Vaccines, Combination Vaccines, Men B Vaccine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 189 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
髄膜炎菌ワクチンの世界市場（タイプ別：多糖類、結合型ワクチン、混合ワクチン、髄膜炎菌B型ワクチン、その他）：業界分析、市場規模、シェア、成長、動向、予測（2022年～2031年）
出版日: 2022年05月27日
発行: Transparency Market Research
ページ情報: 英文 189 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の髄膜炎菌ワクチン市場について調査分析し、市場概要、市場分析、競合情勢など、体系的な情報を提供しています。

目次

第1章 序文

第2章 仮定と調査手法

第3章 エグゼクティブサマリー：世界の髄膜炎菌ワクチン市場

第4章 市場概要

  • イントロダクション
    • 意味
    • 業界の進化/発展
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 世界の髄膜炎菌ワクチン市場の分析と予測（2021年～2031年）

第5章 重要な洞察

  • パイプライン分析
  • 世界の規制シナリオ：地域別
  • COVID-19影響分析

第6章 世界の髄膜炎菌ワクチン市場の分析と予測：タイプ別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 世界の髄膜炎菌ワクチンの市場金額予測（2021年～2031年）：タイプ別
    • 多糖類
    • 結合型ワクチン
    • 混合ワクチン
    • 髄膜炎菌B型ワクチン
  • 世界の髄膜炎菌ワクチン市場の魅力：タイプ別

第7章 世界の髄膜炎菌ワクチン市場の分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 世界の髄膜炎菌ワクチン市場金額予測（2021年～2031年）：エンドユーザー別
    • 小売薬局
    • 病院薬局
    • その他（オンライン薬局、ドラッグストア）
  • 世界の髄膜炎菌ワクチン市場の魅力：エンドユーザー別

第8章 世界の髄膜炎菌ワクチン市場の分析と予測：地域別

  • 主な調査結果
  • 世界の髄膜炎菌ワクチン市場金額予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東およびアフリカ
  • 世界の髄膜炎菌ワクチン市場の魅力：国/地域別

第9章 北米の髄膜炎菌ワクチン市場の分析と予測

第10章 欧州の髄膜炎菌ワクチン市場の分析と予測

第11章 アジア太平洋の髄膜炎菌ワクチン市場の分析と予測

第12章 ラテンアメリカの髄膜炎菌ワクチン市場の分析と予測

第13章 中東およびアフリカの髄膜炎菌ワクチン市場の分析と予測

第14章 競合情勢

  • 市場参入企業－競合マトリックス（企業の層と規模別）
  • 市場シェア分析（2021年）：企業別
  • 企業プロファイル
    • Sanofi SA
    • Novartis International
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Nuron Biotech.
    • JN-International Medical Corporation.
    • Serum Institute of India Ltd
    • Baxter International
図表

List of Tables

  • Table 01: Global Meningococcal Vaccine Market Pipeline Analysis
  • Table 02: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
  • Table 03: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide Meningococcal Vaccines, 2022-2031
  • Table 04: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Meningococcal Vaccines, 2022-2031
  • Table 05: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Meningococcal Vaccines, 2022-2031
  • Table 06: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Meningococcal Vaccines, 2022-2031
  • Table 07: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031
  • Table 08: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Region, 2022-2031
  • Table 09: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country, 2022-2031
  • Table 10: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
  • Table 11: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022-2031
  • Table 12: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022-2031
  • Table 13: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022-2031
  • Table 14: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022-2031
  • Table 15: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031
  • Table 16: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022-2031
  • Table 17: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
  • Table 18: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022-2031
  • Table 19: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022-2031
  • Table 20: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022-2031
  • Table 21: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022-2031
  • Table 22: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031
  • Table 23: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022-2031
  • Table 24: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
  • Table 25: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022-2031
  • Table 26: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022-2031
  • Table 27: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022-2031
  • Table 28: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022-2031
  • Table 29: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031
  • Table 30: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022-2031
  • Table 31: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
  • Table 32: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022-2031
  • Table 33: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022-2031
  • Table 34: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022-2031
  • Table 35: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022-2031
  • Table 36: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031
  • Table 37: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022-2031
  • Table 38: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
  • Table 39: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022-2031
  • Table 40: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022-2031
  • Table 41: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022-2031
  • Table 42: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022-2031
  • Table 43: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031

List of Figures

  • Figure 01: Global Meningococcal Vaccines Market Size (US$ Bn) and Distribution, by Region, 2022 and 2031
  • Figure 02: Market Snapshot of Global Meningococcal Vaccines Market
  • Figure 03: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
  • Figure 04: Market Value Share, by Type, 2021
  • Figure 05: Market Value Share, by End-user, 2021
  • Figure 06: Market Value Share, by Region, 2021
  • Figure 07: Global Meningococcal Vaccines Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 08: Global Meningococcal Vaccines Market Attractiveness, by Type2022-2031
  • Figure 09: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Polysaccharide Vaccines, 2022-2031
  • Figure 10: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Conjugate Vaccines, 2022-2031
  • Figure 11: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, Combination Vaccines, 2022-2031
  • Figure 12: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Men B Vaccines, 2021
  • Figure 13: Global Meningococcal Vaccines Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 14: Global Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
  • Figure 15: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2022-2031
  • Figure 16: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2022-2031
  • Figure 17: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2022-2031
  • Figure 18: Global Meningococcal Vaccines Market Value Share (%), by Region, 2022 and 2031
  • Figure 19: Global Meningococcal Vaccines Market Attractiveness, by Region2022-2031
  • Figure 20: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
  • Figure 21: North America Meningococcal Vaccines Market Value Share (%), by Country, 2022 and 2031
  • Figure 22: North America Meningococcal Vaccines Market Attractiveness, by Country2022-2031
  • Figure 23: North America Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
  • Figure 24: North America Meningococcal Vaccines Market Attractiveness, by Type2022-2031
  • Figure 25: North America Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
  • Figure 26: North America Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
  • Figure 27: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
  • Figure 28: Europe Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
  • Figure 29: Europe Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022-2031
  • Figure 30: Europe Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
  • Figure 31: Europe Meningococcal Vaccines Market Attractiveness, by Type2022-2031
  • Figure 32: Europe Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
  • Figure 33: Europe Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
  • Figure 34: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
  • Figure 35: Asia Pacific Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
  • Figure 36: Asia Pacific Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022-2031
  • Figure 37: Asia Pacific Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
  • Figure 38: Asia Pacific Meningococcal Vaccines Market Attractiveness, by Type2022-2031
  • Figure 39: Asia Pacific Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
  • Figure 40: Asia Pacific Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
  • Figure 41: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
  • Figure 42: Latin America Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
  • Figure 43: Latin America Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022-2031
  • Figure 44: Latin America Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
  • Figure 45: Latin America Meningococcal Vaccines Market Attractiveness, by Type2022-2031
  • Figure 46: Latin America Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
  • Figure 47: Latin America Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
  • Figure 48: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
  • Figure 49: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
  • Figure 50: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022-2031
  • Figure 51: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
  • Figure 52: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Type2022-2031
  • Figure 53: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
  • Figure 54: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
  • Figure 55: Global Meningococcal Vaccines Market Share, by Company, 2018
  • Figure 56: Baxter International, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016-2018
  • Figure 57: Baxter International, Inc. Breakdown of Net Sales (%), by Region, 2018
  • Figure 58: Pfizer Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016-2018
  • Figure 59: Pfizer Inc. Breakdown of Net Sales (%), by Region, 2018
  • Figure 60: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2014-2021
  • Figure 61: Novartis AG Breakdown of Net Sales, by Region, 2021
  • Figure 62: Novartis AG Breakdown of Net Sales, by Business Segment, 2021
  • Figure 63: Novartis AG Breakdown of Net Sales, by Innovative Medicines Business Units, 2021
  • Figure 64: Sanofi S.A Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2021
  • Figure 65: Sanofi S.A Breakdown of Net Sales (%), by Business Segment, 2021
  • Figure 66: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2021
  • Figure 67: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2021
目次
Product Code: TMRGL1666

The report provides revenue of the global meningococcal vaccines market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global meningococcal vaccines market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the meningococcal vaccines market.

The report delves into the competitive landscape of the global meningococcal vaccines market. Key players operating in the global meningococcal vaccines market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global meningococcal vaccines market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Meningococcal Vaccines Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Meningococcal Vaccines Market Analysis and Forecast, 2021-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Regulatory Scenario by Region/globally
  • 5.3. Covid-19 Impact analysis

6. Global Meningococcal Vaccines Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
    • 6.3.1. Polysaccharide
      • 6.3.1.1. Menomune
      • 6.3.1.2. Mencevax
      • 6.3.1.3. NmVac4
      • 6.3.1.4. Others
    • 6.3.2. Conjugate Vaccines
      • 6.3.2.1. Menactra
      • 6.3.2.2. Menveo
      • 6.3.2.3. NeisVac-C
      • 6.3.2.4. Nimenrix
      • 6.3.2.5. Others
    • 6.3.3. Combination Vaccines
      • 6.3.3.1. MenHibrix
      • 6.3.3.2. Menitorix
    • 6.3.4. Men B Vaccines
      • 6.3.4.1. Bexsero
      • 6.3.4.2. Trumenba
  • 6.4. Global Meningococcal Vaccines Market Attractiveness, by Type

7. Global Meningococcal Vaccines Market Analysis and Forecast, by End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
    • 7.3.1. Retail Pharmacies
    • 7.3.2. Hospital Pharmacies
    • 7.3.3. Others (online pharmacies, drug stores)
  • 7.4. Global Meningococcal Vaccines Market Attractiveness, by End-user

8. Global Meningococcal Vaccines Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Global Meningococcal Vaccines Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Global Meningococcal Vaccines Market Attractiveness, by Country/Region

9. North America Meningococcal Vaccines Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. North America Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
    • 9.2.1. Polysaccharide
      • 9.2.1.1. Menomune
      • 9.2.1.2. Mencevax
      • 9.2.1.3. NmVac4
      • 9.2.1.4. Others
    • 9.2.2. Conjugate Vaccines
      • 9.2.2.1. Menactra
      • 9.2.2.2. Menveo
      • 9.2.2.3. NeisVac-C
      • 9.2.2.4. Nimenrix
      • 9.2.2.5. Others
    • 9.2.3. Combination Vaccines
      • 9.2.3.1. MenHibrix
      • 9.2.3.2. Menitorix
    • 9.2.4. Men B Vaccines
      • 9.2.4.1. Bexsero
      • 9.2.4.2. Trumenba
  • 9.3. North America Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
    • 9.3.1. Retail Pharmacies
    • 9.3.2. Hospital Pharmacies
    • 9.3.3. Others (online pharmacies, drug stores)
  • 9.4. North America Meningococcal Vaccines Market Value Forecast, by Country, 2021-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. North America Meningococcal Vaccines Market Attractiveness Analysis
    • 9.5.1. By Type
    • 9.5.2. By End-user
    • 9.5.3. By Country

10. Europe Meningococcal Vaccines Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Europe Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
    • 10.2.1. Polysaccharide
      • 10.2.1.1. Menomune
      • 10.2.1.2. Mencevax
      • 10.2.1.3. NmVac4
      • 10.2.1.4. Others
    • 10.2.2. Conjugate Vaccines
      • 10.2.2.1. Menactra
      • 10.2.2.2. Menveo
      • 10.2.2.3. NeisVac-C
      • 10.2.2.4. Nimenrix
      • 10.2.2.5. Others
    • 10.2.3. Combination Vaccines
      • 10.2.3.1. MenHibrix
      • 10.2.3.2. Menitorix
    • 10.2.4. Men B Vaccines
      • 10.2.4.1. Bexsero
      • 10.2.4.2. Trumenba
  • 10.3. Europe Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
    • 10.3.1. Retail Pharmacies
    • 10.3.2. Hospital Pharmacies
    • 10.3.3. Others (online pharmacies, drug stores)
  • 10.4. Europe Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Europe Meningococcal Vaccines Market Attractiveness Analysis
    • 10.5.1. By Type
    • 10.5.2. By End-user
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Meningococcal Vaccines Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
    • 11.2.1. Polysaccharide
      • 11.2.1.1. Menomune
      • 11.2.1.2. Mencevax
      • 11.2.1.3. NmVac4
      • 11.2.1.4. Others
    • 11.2.2. Conjugate Vaccines
      • 11.2.2.1. Menactra
      • 11.2.2.2. Menveo
      • 11.2.2.3. NeisVac-C
      • 11.2.2.4. Nimenrix
      • 11.2.2.5. Others
    • 11.2.3. Combination Vaccines
      • 11.2.3.1. MenHibrix
      • 11.2.3.2. Menitorix
    • 11.2.4. Men B Vaccines
      • 11.2.4.1. Bexsero
      • 11.2.4.2. Trumenba
  • 11.3. Asia Pacific Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
    • 11.3.1. Retail Pharmacies
    • 11.3.2. Hospital Pharmacies
    • 11.3.3. Others (online pharmacies, drug stores)
  • 11.4. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Asia Pacific Meningococcal Vaccines Market Attractiveness Analysis
    • 11.5.1. By Type
    • 11.5.2. By End-user
    • 11.5.3. By Country/Sub-region

12. Latin America Meningococcal Vaccines Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Latin America Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
    • 12.2.1. Polysaccharide
      • 12.2.1.1. Menomune
      • 12.2.1.2. Mencevax
      • 12.2.1.3. NmVac4
      • 12.2.1.4. Others
    • 12.2.2. Conjugate Vaccines
      • 12.2.2.1. Menactra
      • 12.2.2.2. Menveo
      • 12.2.2.3. NeisVac-C
      • 12.2.2.4. Nimenrix
      • 12.2.2.5. Others
    • 12.2.3. Combination Vaccines
      • 12.2.3.1. MenHibrix
      • 12.2.3.2. Menitorix
    • 12.2.4. Men B Vaccines
      • 12.2.4.1. Bexsero
      • 12.2.4.2. Trumenba
  • 12.3. Latin America Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
    • 12.3.1. Retail Pharmacies
    • 12.3.2. Hospital Pharmacies
    • 12.3.3. Others (online pharmacies, drug stores)
  • 12.4. Latin America Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Latin America Meningococcal Vaccines Market Attractiveness Analysis
    • 12.5.1. By Type
    • 12.5.2. By End-user
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Meningococcal Vaccines Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
    • 13.2.1. Polysaccharide
      • 13.2.1.1. Menomune
      • 13.2.1.2. Mencevax
      • 13.2.1.3. NmVac4
      • 13.2.1.4. Others
    • 13.2.2. Conjugate Vaccines
      • 13.2.2.1. Menactra
      • 13.2.2.2. Menveo
      • 13.2.2.3. NeisVac-C
      • 13.2.2.4. Nimenrix
      • 13.2.2.5. Others
    • 13.2.3. Combination Vaccines
      • 13.2.3.1. MenHibrix
      • 13.2.3.2. Menitorix
    • 13.2.4. Men B Vaccines
      • 13.2.4.1. Bexsero
      • 13.2.4.2. Trumenba
  • 13.3. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
    • 13.3.1. Retail Pharmacies
    • 13.3.2. Hospital Pharmacies
    • 13.3.3. Others (online pharmacies, drug stores)
  • 13.4. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Middle East & Africa Meningococcal Vaccines Market Attractiveness Analysis
    • 13.5.1. By Type
    • 13.5.2. By End-user
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (by tier and size of companies)
  • 14.2. Market Share Analysis, by Company, 2021
  • 14.3. Company Profiles
    • 14.3.1. Sanofi SA
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Strategic Overview
    • 14.3.2. Novartis International
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Strategic Overview
    • 14.3.3. GlaxoSmithKline plc
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Strategic Overview
    • 14.3.4. Pfizer Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Strategic Overview
    • 14.3.5. Nuron Biotech.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Strategic Overview
    • 14.3.6. JN-International Medical Corporation.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Strategic Overview
    • 14.3.7. Serum Institute of India Ltd
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Strategic Overview
    • 14.3.8. Baxter International
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Strategic Overview